Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Fidelio Capital in connection with its investment in Hemfrid
Mandate

Vinge has advised Fidelio Capital in connection with its investment in Hemfrid

August 27, 2021 M&A IT, Telecommunications and Outsourcing Corporate Commercial Employment and Benefits Real Estate and Construction Intellectual Property

Vinge has advised Fidelio Capital AB in its majority investment in Hemfrid i Sverige AB, the leading player within the home service industry in Sweden, with a revenue exceeding MSEK 700 and more than 2,000 employees in 2020. The transaction is subject to customary regulatory approvals and is expected to be completed during the second half of 2021.

Vinge’s team consisted of, among others, Daniel Rosvall, Jonas Bergström, Joacim Rydergård, Filip Öhrner, Christa Anttila, Hannah Kajlinger, Annie Fällström and Amanda Steen (M&A), Karolina Fuhrman and Mika Jordan (Corporate Commercial and IT), Felizia Wiker (IPR), Gustav Lindgren and Carl Östlund (Employment), Karolina Cohrs (Real Estate), and Sara Dahlros Sköld (VDR Assistant).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025